AI-generated analysis. Always verify with the original filing.
Acumen Pharmaceuticals reported financial results for the year ended December 31, 2025, with net loss of $121.3 million, R&D expenses of $104.9 million, and cash, cash equivalents and marketable securities of $116.9 million expected to fund operations into early 2027. The company provided business highlights including ALTITUDE-AD Phase 2 topline results expected late 2026, EBD program IND targeted mid-2027, and a $35.75 million private placement completed March 16, 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
of this Report (including Exhibit 99.2), is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject
Financial Statements and Exhibits. (d). Exhibits Exhibit No. Description 99.1 Earnings Press Release, dated March 26, 2026 99.2 Corporate Presentation, dated Ma
| Metric | Value | Basis |
|---|---|---|
| Research and Development Expenses | $104.90 | GAAP |
| General and Administrative Expenses | $18.90 | GAAP |
| Loss from Operations | $123.80 | GAAP |
| Net Loss | $121.30 | GAAP |
| Net Loss per Common Share, Basic and Diluted | $2.00 | GAAP |